MedTrace Logo

Rituximab in the Treatment of Graves' Disease

NCT00150111 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-10-06

No results posted yet for this study

Summary

Aim:

In a phase II pilot study encompassing 20 patients with Graves' disease to evaluate the effect of rituximab:

1\. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies, anti-TPO)

Conditions

  • Graves´ Disease
  • Thyroid Associated Ophthalmopathy

Interventions

DRUG

Methimazole

DRUG

Rituximab

BIOLOGICAL

Immunization with various vaccines

Sponsors & Collaborators

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Daniel El-Fassi, MD · Odense University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150111 on ClinicalTrials.gov